From the CMS doc “Medicare Drug Value Negotiation Program: Chosen Medicine for Preliminary Value
Applicability 12 months 2027“:
On January 17, 2025, CMS introduced the collection of the beneath checklist of 15 medicine lined below Medicare Half D for the second cycle of negotiations (preliminary worth applicability 12 months 2027), primarily based on complete gross lined prescription drug prices below Medicare Half D and different standards as required by the regulation.
With the Trump inauguration to happen on Monday, will the Medicare Drug Value Negotiation course of change with the brand new administration? Anna Kaltenboeck notes in EndPoints Information:
…the following administration is not going to have “blanket authority to alter the core elements of the regulation,” sure facets of the method could be modified with out legislative motion.
For instance, CMS might alter its steering or the way it interprets elements of the regulation, akin to what number of instances it meets with drugmakers, or what number of listening classes it holds. “The diploma to which they play hardball with producers within the course of might change,” she stated.
